Literature DB >> 29983266

Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers.

Shashi N Kapadia1, Kristen M Marks2.   

Abstract

This article proposes a strategy for primary care providers to begin treating patients with hepatitis C virus (HCV). We are motivated by the need to expand HCV treatment and by developments that have simplified treatment for most patients. This article presents 5 steps to achieving quality HCV treatment in the primary care setting: (1) accurate diagnosis via reflex testing; (2) risk stratification and identifying comorbidities via pretreatment evaluation; (3) simple, once-daily, pan-genotypic HCV treatment regimens; (4) minimized on-treatment monitoring: and (5) posttreatment monitoring and high-quality care for comorbidities such as cirrhosis and injection drug use. We provide indications for referral to specialists: notably children, patients with genotype 3 and cirrhosis, advanced liver or kidney disease, previous treatment failures, drug interactions with recommended regimens, and hepatitis B co-infection. Finally, potential barriers for providers are discussed, as well as further research findings and policy interventions that can promote HCV treatment in the primary care setting. We believe that a substantial portion of patients with HCV can be treated safely and effectively by nonspecialists and that the engagement of primary care providers is critical to efforts to end the HCV epidemic.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HCV; direct-acting antivirals; hepatitis C virus; nonspecialist; primary care; treatment

Mesh:

Substances:

Year:  2018        PMID: 29983266      PMCID: PMC6448786          DOI: 10.1016/j.clinthera.2018.05.010

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  46 in total

1.  Check Hep C: A Community-Based Approach to Hepatitis C Diagnosis and Linkage to Care in High-Risk Populations.

Authors:  Mary M Ford; Ashly E Jordan; Nirah Johnson; Eric Rude; Fabienne Laraque; Jay K Varma; Holly Hagan
Journal:  J Public Health Manag Pract       Date:  2018 Jan/Feb

2.  Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Authors:  Tarik Asselah; Kris V Kowdley; Neddie Zadeikis; Stanley Wang; Tarek Hassanein; Yves Horsmans; Massimo Colombo; Filipe Calinas; Humberto Aguilar; Victor de Ledinghen; Parvez S Mantry; Christophe Hezode; Rui Tato Marinho; Kosh Agarwal; Frederik Nevens; Magdy Elkhashab; Jens Kort; Ran Liu; Teresa I Ng; Preethi Krishnan; Chih-Wei Lin; Federico J Mensa
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-22       Impact factor: 11.382

3.  Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.

Authors:  Lauren A Canary; R Monina Klevens; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

4.  Comparison of serial Hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation.

Authors:  Howard B Gale; D Robert Dufour; Nazia N Qazi; Virginia L Kan
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

5.  Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy.

Authors:  Ryan P Westergaard; Lauren J Stockman; Heather A Hyland; Sheila M Guilfoyle; John J Fangman; James M Vergeront
Journal:  J Prim Care Community Health       Date:  2014-11-24

6.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

7.  Trends in HCV RNA testing among HCV antibody-positive persons in care, 2003-2010.

Authors:  Philip R Spradling; Xin Tong; Loralee B Rupp; Anne C Moorman; Mei Lu; Eyasu H Teshale; Stuart C Gordon; Vinutha Vijayadeva; Joseph A Boscarino; Mark A Schmidt; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2014-07-02       Impact factor: 9.079

8.  Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Authors:  Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

9.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Authors:  Gary L Davis; Miriam J Alter; Hashem El-Serag; Thierry Poynard; Linda W Jennings
Journal:  Gastroenterology       Date:  2009-10-25       Impact factor: 22.682

10.  Evaluating a Collaborative Approach to Improve Prior Authorization Efficiency in the Treatment of Hepatitis C Virus.

Authors:  Emily E Dunn; Kathryn Vranek; Lauren M Hynicka; Janet Gripshover; Darryn Potosky; T Joseph Mattingly
Journal:  Qual Manag Health Care       Date:  2017 Jul/Sep       Impact factor: 0.926

View more
  17 in total

1.  A Simplified Algorithm for the Management of Hepatitis C Infection.

Authors:  Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-05

2.  A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.

Authors:  B L Norton; A H Litwin
Journal:  Clin Infect Dis       Date:  2020-05-23       Impact factor: 9.079

Review 3.  Hepatitis C elimination: a Public Health Perspective.

Authors:  Radha K Dhiman; Gagandeep S Grover; Madhumita Premkumar
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

4.  Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?

Authors:  Ping Du; Xi Wang; Lan Kong; Jeah Jung
Journal:  Telemed J E Health       Date:  2020-09-02       Impact factor: 3.536

5.  Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.

Authors:  Xavier Forns; Jordan J Feld; Douglas E Dylla; Stanislas Pol; Kazuaki Chayama; Jinlin Hou; Jeong Heo; Pietro Lampertico; Ashley Brown; Mark Bondin; Fernando Tatsch; Margaret Burroughs; John Marcinak; Zhenzhen Zhang; Amanda Emmett; Stuart C Gordon; Ira M Jacobson
Journal:  Adv Ther       Date:  2021-05-22       Impact factor: 3.845

6.  Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era.

Authors:  Shashi N Kapadia; Phyllis Johnson; Kristen M Marks; Bruce R Schackman; Yuhua Bao
Journal:  Med Care       Date:  2021-09-01       Impact factor: 3.178

7.  Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017.

Authors:  Ping Du; Xi Wang; Lan Kong; Thomas Riley; Jeah Jung
Journal:  Am J Prev Med       Date:  2020-11-19       Impact factor: 5.043

8.  A Telementoring Program and Hepatitis C Virus Care in Rural Patients.

Authors:  Ping Du; Xin Yin; Lan Kong; Jeah Jung
Journal:  Telemed Rep       Date:  2021-05-13

9.  A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.

Authors:  A Seaman; C A King; T Kaser; A Geduldig; W Ronan; R Cook; B Chan; X A Levander; K C Priest; P T Korthuis
Journal:  Int J Drug Policy       Date:  2021-07-27

10.  Room for Improvement: Rates of Birth Cohort Hepatitis C Screening in Primary Care Practices-A WWAMI Region Practice and Research Network Study.

Authors:  Allison M Cole; Gina A Keppel; Laura-Mae Baldwin; Ryan Gilles; John Holmes; Chardonnay Vance; Bill Kriesgman; Adriana Linares; Jaime Hornecker; Elizabeth Paddock; Winslow Gerrish; William Alto; Debra Gould; Jon Neher
Journal:  J Prim Care Community Health       Date:  2019 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.